GlassScriptPhysician profile
Scott B Hammerman
NPI 1124382023
$9,137.30
in general payments reported to CMS, 2019-2025
29 companies · $861 in 2025
The $861 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,665 · 2020: $1,161 · 2021: $1,493 · 2022: $888 · 2023: $799 · 2024: $1,270 · 2025: $861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,641 · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,640.85 |
| Education | $289.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,498.81 | 2019-2025 | |
| Janssen Biotech, INC. | $1,061.98 | 2019-2025 | Tremfya |
| Galderma Laboratories, L.P. | $891.87 | 2019-2024 | Aklief |
| Revance Therapeutics, INC. | $576.85 | 2024-2025 | Daxxify |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $562.38 | 2019-2022 | |
| Dermavant Sciences, INC. | $518.83 | 2023-2024 | Vtama |
| Leo Pharma INC. | $389.20 | 2019-2022 | |
| Lilly USA, LLC | $367.92 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Mayne Pharma Commercial LLC | $358.29 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $344.77 | 2019-2025 | |
| Genzyme Corporation | $330.20 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $284.12 | 2019-2023 | Absorica Ld, Winlevi |
| Incyte Corporation | $282.24 | 2021-2023 | Opzelura |
| Pfizer INC. | $263.66 | 2019-2024 | |
| Amgen INC. | $204.98 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $167.25 | 2019-2024 | Dupixent |
| Celgene Corporation | $150.41 | 2019 | |
| Vyne Pharmaceuticals INC. | $146.02 | 2020-2021 | |
| Dermira, INC. | $133.62 | 2019-2020 | |
| Almirall LLC | $109.39 | 2019-2022 | |
| Allergan, INC. | $97.33 | 2019 | |
| Epi Health, LLC | $95.37 | 2019-2022 | |
| Ucb, INC. | $80.63 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $50.80 | 2024 | Sotyktu |
| Merck Sharp & Dohme LLC | $49.97 | 2019 | |
| Aclaris Therapeutics, INC. | $43.87 | 2019 | |
| Journey Medical Corporation | $34.26 | 2020-2021 | |
| Organon LLC | $26.55 | 2025 | |
| Mission Pharmacal Company | $15.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Hammerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.